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A B S T R A C T   
Increased neuronal expression of the Na-K-2Cl cotransporter NKCC1 has been implicated in the generation of 
seizures and epilepsy. However, conclusions from studies on the NKCC1-specific inhibitor, bumetanide, are 
equivocal, which is a consequence of the multiple potential cellular targets and poor brain penetration of this 
drug. Here, we used Nkcc1 knockout (KO) and wildtype (WT) littermate control mice to study the ictogenic and 
epileptogenic effects of intrahippocampal injection of kainate. Kainate (0.23 μg in 50 nl) induced limbic status 
epilepticus (SE) in both KO and WT mice with similar incidence, latency to SE onset, and SE duration, but the 
number of intermittent generalized convulsive seizures during SE was significantly higher in Nkcc1 KO mice, 
indicating increased SE severity. Following SE, spontaneous recurrent seizures (SRS) were recorded by contin-
uous (24/7) video/EEG monitoring at 0-1, 4-5, and 12-13 weeks after kainate, using depth electrodes in the 
ipsilateral hippocampus. Latency to onset of electrographic SRS and the incidence of electrographic SRS were 
similar in WT and KO mice. However, the frequency of electrographic seizures was lower whereas the frequency 
of electroclinical seizures was higher in Nkcc1 KO mice, indicating a facilitated progression from electrographic 
to electroclinical seizures during chronic epilepsy, and a more severe epileptic phenotype, in the absence of 
NKCC1. The present findings suggest that NKCC1 is dispensable for the induction, progression and manifestation 
of epilepsy, and they do not support the widely held notion that inhibition of NKCC1 in the brain is a useful 
strategy for preventing or modifying epilepsy.   
1. Introduction 
The Na-K-2Cl cotransporter NKCC1 (encoded by the Slc12a2 gene) 
mediates active Cl− uptake in a large variety of cell types within and 
outside the brain (Russell, 2000; Markadieu and Delpire, 2014). In the 
brain, NKCC1 is expressed in neurons as well as astroglia and oligo-
dendrocytes (Wilson and Mongin, 2019; Virtanen et al., 2020). During 
development and disease of central neurons, NKCC1 acts together with 
the neuron-specific chloride extruder KCC2 as a major player in setting 
the reversal potential and driving force of the chloride currents medi-
ated by GABAA receptors (Kaila et al., 2014a, 2014b). Because of the role 
of NKCC1 and KCC2 in controlling the efficacy of neuronal inhibition, 
many studies have addressed the potential impact of these ion trans-
porters in the acute generation of seizures (ictogenesis) and in 
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epileptogenesis (reviewed in Kahle et al., 2008; Blaesse et al., 2009; Ben- 
Ari et al., 2012; Miles et al., 2012; Löscher et al., 2013; Kaila et al., 
2014a, 2014b; Auer et al., 2020; Liu et al., 2020). For instance, in hip-
pocampal brain slices from adult patients with temporal lobe epilepsy 
(TLE), downregulation of KCC2 and upregulation of NKCC1 leads to 
depolarizing GABAA receptor responses in a subpopulation of subicular 
principal neurons (Cohen et al., 2002; Huberfeld et al., 2007; Munoz 
et al., 2007). We and others have reported similar findings in the 
kindling and pilocarpine rat models of TLE (Rivera et al., 2002; Okabe 
et al., 2003; Pathak et al., 2007; Li et al., 2008; Brandt et al., 2010; 
Barmashenko et al., 2011; Kourdougli et al., 2017). 
The potential role of upregulated neuronal NKCC1 in epilepsy has led 
to the suggestion that the NKCC1 inhibitor bumetanide may exert 
anticonvulsant and antiepileptogenic effects (Kahle and Staley, 2008; 
Kahle et al., 2008; Ben-Ari et al., 2012; Ben-Ari, 2017; Kharod et al., 
2019; Auer et al., 2020; Liu et al., 2020). However, both preclinical and 
clinical data on bumetanide are controversial, which may be due to the 
fact that this loop diuretic only poorly penetrates into the neonatal or 
adult brain and consequently, at clinically used doses (0.05-0.3 mg/kg in 
pediatric patients, 0.5-2 mg in adult patients), does not reach brain 
levels that are sufficient to inhibit neuronal NKCC1 (Brandt et al., 2010; 
Löscher et al., 2013; Cleary et al., 2013; Puskarjov et al., 2014; Töllner 
et al., 2014; Brandt et al., 2018; Hampel et al., 2021). 
Surprisingly, despite the availability of Slc12a2 (or Nkcc1) knockout 
(KO) mice, they have only rarely been used to study the role of NKCC1 in 
ictogenesis and epileptogenesis. Constitutive Nkcc1 KO mice are deaf 
and (as a result of their inner ear defects) exhibit unusual head postures, 
circling behavior, rapid spinning and difficulty in maintaining balance 
(Markadieu and Delpire, 2014). Zhu et al. (2008) reported that absence 
of NKCC1 in neonatal CA3 pyramidal neurons, through genetic manip-
ulation or through bumetanide inhibition, results in a significant increase 
in cell excitability. Furthermore, the proconvulsant agent 4-aminopyri-
dine induced seizure-like events in NKCC1-null mice but not in wild-
type (WT) mice (Zhu et al., 2008). Sipilä et al. (2009) found that 
hippocampal slices from Nkcc1− /− neonates of the mouse line used in 
the present study (Flagella et al., 1999) generate endogenous network 
events similar to giant depolarizing potential (GDPs), most likely based 
on homeostatic upregulation of intrinsic neuronal excitability as a 
response to the lack of NKCC1-mediated GABAergic excitation; 
furthermore, glutamatergic network activity was enhanced in the 
Nkcc1− /− hippocampus. 
Systemic treatment with clinically relevant doses of bumetanide 
(0.1-0.2 mg/kg) has been reported to exert anticonvulsant and anti-
epileptogenic effects in neonatal rodent models (Dzhala et al., 2005; 
Koyama et al., 2012; Cleary et al., 2013), but other studies have refuted 
this (Kang et al., 2015; Johne et al., 2021; see also Vanhatalo et al., 
2009), and even high systemic doses of bumetanide did not alter epi-
leptogenesis in the pilocarpine model in adult rats (Brandt et al., 2010). 
Interestingly, bumetanide (0.2 or 2 mg/kg) was reported to reduce 
kainate-induced seizure progression and the development of pharma-
coresistant status epilepticus (SE) in adult mice (Sivakumaran and 
Maguire, 2016). 
To our knowledge, the present study is the first that uses Nkcc1 KO 
mice to determine the effect of genetic NKCC1 deletion on epilepto-
genesis. For this purpose, we used the intrahippocampal kainate mouse 
model of mesial TLE, in which increased NKCC1 expression has been 
reported to occur four weeks after SE in the ipsilateral hippocampus 
(Stamboulian-Platel et al., 2016). Focal, unilateral injection of kainate 
into the hippocampus mimics the onset and progression of human mesial 
TLE more closely than models with systemic administration of convul-
sants such as kainate or pilocarpine, since it causes unilateral cell death 
similar to the hippocampal sclerosis associated with clinical TLE (Guil-
lemain et al., 2012; Duveau and Roucard, 2017). 
In the present study, upregulation of NKCC1 expression was 
observed already at 24 h after SE in WT mice. Strikingly, the Nkcc1 KO 
mice exhibited a more severe SE than WT littermates, and the 
progression of spontaneous electrographic to electroclinical seizures 
was facilitated, resulting in a more severe epileptic phenotype. These 
data contradict the view that either the presence or upregulation of 
neuronal NKCC1 are critically involved in the development of epilepsy 
and that, as a consequence, pharmacological inhibition of NKCC1 may 
prevent or attenuate epileptogenesis after brain insults. 
2. Materials and methods 
2.1. Animals 
The mouse strain with a disruption of Slc12a2 coding for NKCC1 
(Flagella et al., 1999) was obtained from The Jackson Laboratory and 
backcrossed into C57BL/6. WT, heterozygous, and homozygous Nkcc1 
KO mice of both sexes were generated from heterozygous matings. 
Genotyping was performed by using ear samples (ear punches) as 
described previously (Flagella et al., 1999). The germ-line homozygous 
Nkcc1 KO animals have no expression of NKCC1 in any cells and tissues. 
In the present study, male and female homozygous Nkcc1− /− mice 
and WT littermates were used. Animals were housed at 22-24 ◦C, hu-
midity 30-50%, lights on from 6:00 am to 6:00 pm. Food (Altromin 1324 
standard diet; Altromin, Lage, Germany) and water were freely avail-
able. Experiments were performed according to the EU council directive 
2010/63/EU and the German Law on Animal Protection (“Tier-
schutzgesetz”). Ethical approval for the study was granted by an ethical 
committee (according to §15 of the Tierschutzgesetz) and the govern-
ment agency (Lower Saxony State Office for Consumer Protection and 
Food Safety; LAVES) responsible for approval of animal experiments in 
Lower Saxony (reference number for this project: 15/1825). All efforts 
were made to minimize both the suffering and the number of animals. 
All animal experiments in this study are reported in accordance with the 
ARRIVE guidelines (Kilkenny et al., 2010). Furthermore, in line with 
guiding principles for biomedicine (Clayton and Collins, 2014), we 
accounted for sex as a biological variable in the present preclinical 
experiments. 
2.2. Intrahippocampal kainate model 
In this model, SE is induced by unilateral injection of kainate into the 
dorsal hippocampus (Suzuki et al., 1995; Bouilleret et al., 1999). Mice 
(age 10-15 weeks) were anesthetized with chloral hydrate (500 mg/kg i. 
p.), and kainate monohydrate (0.23 μg in 50 nl saline; i.e., 0.92 nM; 
Sigma-Aldrich, Steinheim, Germany), was stereotaxically injected into 
the right CA1 of the dorsal hippocampus over 60 s with a 0.5 μl 
microsyringe. In preliminary experiments on the mice used here, ste-
reotaxic coordinates (according to Paxinos and Franklin, 2012) were 
determined by histological verification of the injection site in CA1. 
These coordinates were then used for the experiments on the WT and 
Nkcc1 KO mice: ♀AP: − 1.90 mm, L: − 1.40 mm, V: − 1.70 mm, ♂ AP: 
− 1.90 mm, L: − 1.60 mm, V: − 2.0 mm. After injection of kainate, the 
needle was maintained in situ for additional 2 min to limit reflux along 
the injection track. For EEG recordings, the animals were immediately 
implanted with bipolar electrodes aimed at the site of kainate injection 
in the ipsilateral CA1, using the same coordinates as for kainate injection 
(see Gröticke et al., 2008). During all surgical procedures and for about 
1 h thereafter mice were kept on a warming pad to avoid hypothermia. 
The dose of kainate used in the present experiments (0.92 nM) was 
based on preliminary dose-effect experiments in male C57BL/6 WT 
mice, in which incidence of SE, mortality, and spontaneous recurrent 
seizures (SRS) were compared in groups of animals injected with either 
0.92, 1.25, or 1.5 nM in the hippocampus. Incidence of SE and SRS was 
the same in all groups, but mortality was lowest in the 0.92 nM group. 
In the present experiments with intrahippocampal injection of 0.92 
nM kainate, WT littermates were always injected together with homo-
zygous KO mice, using the same batch of kainate. Thus, there was no 
systematic difference in kainate injection between WT and KO mice. 
P. Hampel et al.                                                                                                                                                                                                                                 
Neurobiology of Disease 152 (2021) 105297
3
In addition to the kainate-treated mice, additional age-matched WT 
mice (11 male, 11 female) were prepared as sham controls. These mice 
were treated in the same way as the kainate mice except that they 
received intrahippocampal injection of 50 nl saline instead of kainate. 
Some experiments were also performed with pilocarpine, using a 
ramping-up i.p. dosing protocol of pilocarpine as described previously 
(Müller et al., 2009). All Nkcc1− /− and littermate controls died before 
developing SE in individual convulsive (tonic-clonic) seizures, due to 
respiratory arrest. High mortality in the pilocarpine model has been 
described previously for C57BL/6 mice (Borges et al., 2003; Müller 
et al., 2009); as a consequence, systemic administration of pilocarpine 
could not be used to study epileptogenesis in the mice used for the 
present study. 
2.3. Video/EEG recording 
After surgery, video-EEG monitoring was used to verify the limbic, 
predominantly nonconvulsive SE induced by kainate. Furthermore, as 
shown in Fig. 1, continuous (24/7) video-EEG monitoring over one week 
after kainate was used to determine the latent period, which, in previous 
experiments, ranged from 0 to 7 days (mean 2.1 days) in male C57BL/6 
mice (Schidlitzki et al., 2020), whereas no clear latent period could be 
determined in female C57BL/6 mice (Twele et al., 2016a). Starting 4 
weeks after SE, i.e., at a time at which the majority of kainate-injected 
mice exhibit SRS (Twele et al., 2016a, 2016b; Schidlitzki et al., 2020), 
continuous video-EEG monitoring over one week was used to compare 
the occurrence of seizures or other EEG abnormalities in kainate- 
injected WT vs. KO mice (Fig. 1). Video-EEG recording for one week 
was repeated after 12 weeks following kainate to determine if the pro-
gression of epilepsy was different between genotypes. 
For EEG-recording, mice were connected via a flexible cable to a 
system consisting of one-channel amplifiers (ADInstruments Ltd., Syd-
ney, Australia) and analog-digital converters (PowerLab 8/30 ML870, 
ADInstruments). The data were recorded and analyzed with LabChart 8 
for Windows software (ADInstruments), sampling rate 200 Hz, time 
constant 0.1 s, low pass filter of 60 Hz, and a 50 Hz notch filter. The EEG- 
recording was directly linked to simultaneous digital video recording 
using one high-resolution infrared camera for up to eight mice (NYCTO 
Vision, CaS Business Services, Wunstorf, Germany). For video/EEG 
monitoring, mice were housed singly in clear plexiglass cages (one per 
cage). For monitoring during the dark phase, infrared LEDs were 
mounted above the cages. 
2.4. Analysis of video-EEG activity during SE, latent period and the 
chronic epileptic state 
Latency to SE onset, SE duration and severity were visually analyzed 
in the video-EEGs recorded from each mouse. During the latent period 
after SE, the EEGs recorded over 7 days after kainate were visually 
examined for onset of spontaneous electrographic seizure activity. 
Furthermore, electrographic and electroclinical seizures occurring in the 
chronic epileptic phase of mice with intrahippocampal kainate injection 
were analyzed visually. 
Mice develop four types of epileptic SRS in this model, i.e., two types 
of electrographic (or nonconvulsive) seizures and two types of electro-
clinical (convulsive) seizures as described in the following. The most 
frequent SRS in this model are the two types of electrographic seizures in 
the the ipsilateral hippocampus without any obvious motor correlates 
(Twele et al., 2016a, 2016b). Based on the findings by Riban et al. 
(2002), we recently characterized these electrographic seizures for 
different mouse strains (Twele et al., 2016a, 2016b; Schidlitzki et al., 
2020) and differentiated between high-voltage sharp waves (HVSWs) 
and hippocampal paroxysmal discharges (HPDs) as summarized in 
Table 1: 
1. HVSWs (see also Fig. 2E-H and movie S1) are characterized by 
high amplitude sharp waves ≥3 times the EEG baseline with a frequency 
of at least 2 Hz (spikes per second), a duration of at least five seconds, 
and an inter-event interval of at least three seconds. The inter-event 
interval is characterized by the occurrence of either no epileptic EEG 
activity, isolated spikes, or spike trains with an amplitude of less than 
three times the baseline. HVSWs can show evolution in frequency or 
pattern, but can also appear uniform. 
2. HPDs (Fig. 2I-L and movie S1) are often longer (over 20 s) than 
typical HVSWs and always show evolution in morphology and fre-
quency. HPDs typically start with large-amplitude HVSWs, followed by a 
train of lower-amplitude spikes (≥ 2 times the baseline) with at least five 
seconds of increased frequency (≥ 5 Hz). As described previously (Twele 
et al., 2016b), based on duration, two types of HPDs occur: short HPDs 
(5-20 s) and, more often, long HPDs (>20 s). In the present study, both 
types were grouped together. Like HVSWs, HPDs also have an inter- 
event interval of at least three seconds, in which either no epileptic 
EEG activity, isolated spikes, or spike trains with an amplitude of less 
than two times baseline are observed (considered as interictal activity). 
For comparison of the frequency of HVSWs and HPDs in WT and KO 
mice, electrographic seizures were counted manually in the EEG during 
Fig. 1. Schematic presentation of the experimental protocol used for the present experiments.  
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the two one-week video/EEG monitoring periods at 4 and 12 weeks post- 
SE. In each recording period, four 30-min periods (at 12:00, 6:00, and 
11:00 pm of day 1 and 6:00 am of day 2) of continuous (24/7) EEG 
monitoring were selected and analyzed for calculation of the average 
number of electrographic seizures occurring per hour. 
In addition to highly frequent electrographic seizures, mice develop 
less frequent focal and generalized electroclinical (convulsive) seizures 
(Twele et al., 2016b), which occur several times per week (Table 1). 
Focal and generalized convulsive electroclinical seizures are character-
ized by a high spike frequency and amplitude, and a typical postictal 
depression of the EEG baseline (Fig. 2M,N and movie S1). For compar-
ison of the frequency of electroclinical seizures in WT and KO mice, 
seizures were counted manually in the video/EEG recordings of the 
seven days of continuous (24/7) recordings at 4 and 12 weeks post-SE. 
Based on the video recordings, the electroclinical seizures were rated 
for severity using the following modified scale by Racine (1972): stage 1, 
behavioral arrest with minor facial clonus (stereotypical sniffing, tremor 
of tactile hair); stage 2, severe facial clonus (head nodding, mouth or 
facial movements); stage 3, unilateral forelimb clonus; stage 4, bilateral 
forelimb clonus with rearing; stage 5, generalized tonic-clonic seizure 
with loss of righting reflexes. Stage 1-2 seizures were considered as focal 
and stage 3-5 seizures as generalized convulsive seizures. Furthermore, 
the average severity and duration of electroclinical seizures was deter-
mined and compared between the two groups. 
Some animals lost their electrode assemblies during the 3 months of 
the trial (see section 3). Thus, the videos were used to quantify elec-
troclinical seizures in such mice. Therefore, the number of mice used for 
final analysis of electrographic and (electro)clinical seizures differs (see 
section 3). Here, it is relevant to note that we did not observe any 
electroclinical uncoupling in any individual during the present study, 
which justifies using the term “electroclinical seizure” in the small group 
of animals where the EEG recording was lost and convulsive seizures 
were seen. 
2.5. Histology 
For histological analysis, mice were deeply anesthetized with chloral 
hydrate (720 mg/kg i.p. in 10 ml) after the last video/EEG recording 
(13-14 weeks after intrahippocampal kainate injection; see Fig. 1) and 
transcardially perfused with 0.01 M phosphate-buffered saline followed 
by 4% paraformaldehyde. The brains were removed after one hour, 
postfixed in 10% sucrose solution (with 4% paraformaldehyde) for 24 h, 
and then transferred to 30% sucrose solution (saline). One mg/ml of 
thymol was added to the sucrose solution if the brains were stored for a 
longer period of time. As previously described (Bröer et al., 2016), four 
series of coronal brain sections (40 μm) were prepared using a cry-
omicrotome and subsequently stained with cresyl violet (containing 
thionin). Sham-treated mice were used as controls. The correct locali-
zation of the kainate injection and EEG electrode in the hippocampus 
was verified in each mouse. 
For determining neurodegeneration in the hippocampus, three 
thionin-stained brain sections (at − 1.34, − 1.70 and − 2.06 mm AP from 
bregma) were semi-quantitatively scored using a scoring system 
described by Gröticke et al. (2008). The left and right hippocampi were 
scanned in a quasi-random fashion and scores were noted for each of the 
subregions of the hippocampal formation (CA1, CA2, CA3a, Ca3c, and 
hilus): score 0 = no obvious damage; score 1 = abnormal appearance of 
the structure without clear evidence of visible neuronal loss; score 2 =
moderate neurodegeneration (lesions involving 20–50% of neurons); 
score 3 = severe neurodegeneration (lesions involving over 50% of 
neurons). Furthermore, the extent of the granule cell dispersion (GCD) 
in the dentate gyrus was visually assessed with a score system: score 0 =
no GCD, score 1 = mild GCD, score 2 = moderate GCD, score 3 = severe 
GCD (Schidlitzki et al., 2017). 
Compared to the extent of cell loss occurring after an SE in CA3c and 
CA1, which can be easily scored by microscopic examination, loss of 
neurons in the dentate hilus is more difficult to assess without cell 
counting. Therefore, in a second step, polymorphic neurons (i.e., mossy 
cells and interneurons) were counted in the dentate hilus of the hippo-
campal formation. Apart from size, neurons were clearly identifiable on 
morphological grounds. Neuronal loss was quantified in the ipsilateral 
hilus at − 1.70 mm AP from bregma). The hilus was defined as the inner 
border of the granule cell layer and two straight lines connecting the tips 
of the granule cell layer and the proximal end of the CA3c region. All 
Table 1 
Comparison of the EEG characteristics of the three main types of seizures 
observed in the intrahippocampal kainate mouse model. These characteristics 
were defined previously in different mouse strains (Twele et al., 2016a, 2016b) 
and verified in the mice used for the present experiments. Seizure frequency 
(mean and range) refers to video/EEG recording in wildtype mice at 4-5 weeks 
after kainate. Fig. 2 gives representative examples of the different seizure types.  
Parameter Type of seizure 


















(HPDs only occur 
in the immediate 




occur in other brain 
regions) 





Fast activity at 




develops with time 




Often not Yes Yes 
Spike 
frequency 
≥2 Hz ≥5 s with ≥5 Hz, 
<3 s interruption 
with <5 Hz 
≥2 Hz, typically 
≥3 Hz 
Amplitude ≥3times baseline Based on evolution 
≥2-3 times 
baseline 
Based on evolution 
≥2-3 times baseline 
Durationa ≥5 s 5- >20 secb ≥10 s 
Frequency 14.6/h (0-33/h) 3.5/h (0-18/h) 4.9/week (0-25) 
Flattening of 




No No Yes 
Inter-event 
interval 







Not clearly visible 
in video recordings 
Not clearly visible 
in video 
recordingsc 




Comments HVSWs can show 
evolution in 
frequency or 
pattern but often 
are rather regular. 
Usually starts with 
HVSW-like 
activity; rate shows 
evolution with ≥5 
Hz for ≥5 s. 




a In arbitrary definition of seizures, a duration of at least 10 s is often applied 
operationally, but there is no official minimum time to define a seizure (Fisher 
et al., 2014). Instead, it is frequently assumed that epileptiform discharges that 
last longer than 2–3 s can be considered as ictal. 
b Based on duration, two types of HPDs: 5-20 s = short HPD, >20 s = long 
HPD. 
c Behavioral arrest with head nodding or stereotyped behavior, such as 
exploration or grooming, were observed concomitantly with HPDs in several 
studies (Riban et al., 2002; Duveau and Roucard, 2017), but this is difficult to 
differentiate from normal activity during continuous video/EEG monitoring. 
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cells within these borders were counted at a 200× magnification 
(Axioscope, Carl Zeiss, Germany). The area of each hilus counted was 
measured with the KS400 software (Carl Zeiss). Neuronal densities 
(neurons per unit area) were calculated on the basis of neuronal counts 
in the hilus and the measured area of the hilus. All neuron counts and 
area measurements were performed by a person who was blinded with 
respect to the origin of the sections. In addition to hilus area, the area of 
the contralateral hippocampus was measured morphometrically at AP 
-1.70 mm in each mouse to determine whether the size of the hippo-
campus differed between WT and KO mice (the contralateral hippo-
campus is not affected by unilateral kainate injection in this model). 
We also thought about performing immunohistochemical analysis of 
the hippocampal expression of NKCC1 following kainate in WT mice, 
but, unfortunately, to the authors’ best knowledge, there are no 
commercially available NKCC1 antibodies that have been demonstrated 
to yield a fully NKCC1-specific signal in brain parenchyma by using 
Nkcc1 KO brain tissue as controls (see Fritschy, 2008). In fact, this ex-
plains much of the inconsistencies in the literature on NKCC1 expression 
patterns in the brain (Virtanen et al., 2020). Thus, we decided to study 
the hippocampal expression of NKCC1 mRNA following kainate in WT 
mice by qPCR (see next section). 
2.6. Quantitative real-time polymerase chain reaction (qPCR) 
Levels of NKCC1 and KCC2 mRNA expression were quantified in 
ipsilateral hippocampi after kainate injection compared to sham injec-
ted (NaCl) mice by reverse transcription and quantitative real time PCR. 
Briefly, WT mice (12 weeks of age) were killed by cervical dislocation 
24 h after kainate injection and brains were cut at the AP location of the 
kainate injection site. Total RNA was extracted from anterior part of the 
ipsilateral hippocampus using RNeasy Plus Mini Kit (Qiagen, Hilden, 
Germany) and defined amounts (210 ng RNA) were reverse-transcribed 
into single stranded cDNA using the iScript RT Supermix for RT-qPCR 
(Bio-Rad, München, Germany) according to the manufacturer’s in-
structions. Quantitative real-time PCR was performed using TaqMan 
Fast Advanced PCR Master Mix (Thermo Fisher Scientific, Bonn, Ger-
many) and Taq man gene expression assays (Thermo Fisher Scientific) 
for KCC2 (Slc12a5, Mm00803929_m1), NKCC1 (Slc12a2, 
Mm01265951_m1) and housekeeping gene β-actin (Actb, 
Mm00607939_s1). Reaction conditions were as follows: 50 ◦C for 2 min, 
95 ◦C for 10 min and 45 cycles of 95 ◦C for 15 s and 52 ◦C for 30 s. qPCR 
analysis was performed using a CFX Connect Real-time PCR System (Bio- 
Rad) and CFX Maestro Software. Expression levels were calculated using 
the 2(-ΔCT) method (Schmittgen and Livak, 2008) with β-actin as an in-
ternal control. 
2.7. Statistics 
Depending on whether data were normally distributed or not, 
parametric or nonparametric tests were used for statistical evaluation. 
For comparison of two independent groups, Student’s t-test or the Mann- 
Whitney U test were used; for paired comparisons, Student’s t-test or the 
Wilcoxon signed rank were used. In case of more than two groups we 
used one-way analysis of variance (ANOVA) with post-hoc testing and 
correction for multiple comparisons. Depending on data distribution, 
ordinary ANOVA or the Kruskal-Wallis test were used, followed by 
Dunn’s or Holm-Sidak’s multiple comparisons tests. For comparison of 
frequencies in a 2 × 2 table, Barnard’s unconditional test (Barnard, 
1947) was used, because this test preserves the significance level and 
generally is more powerful than Fisher’s exact test for moderate to small 
samples (Lydersen et al., 2009). Grubb’s test was used to identify out-
liers (see section 3). Except for Barnard’s unconditional test, all statis-
tical analyses were performed with the Prism 8 software from GraphPad 
(La Jolla, CA, USA). Two-sided tests were used; a P ≤ 0.05 was 
considered significant. The statistical tests used for analyzing the data 
are described in figure and table legends. 
For estimation statistics, analyses were done as described by Ho et al. 
(2019). We directly introduced the raw data in https://www.estimat 
ionstats.com/ and downloaded the results and graphs. In respective 
graphs, the mean difference for two comparisons is shown with Gardner- 
Altman estimation plot. Each mean was plotted on the lower axes as a 
bootstrap sampling distribution. Five thousand bootstrap samples were 
taken; the confidence interval was bias-corrected and accelerated. 
3. Results 
3.1. Phenotype of the Nkcc1− /− mice vs. WT littermates 
Generation of enough WT and homozygous NKCC1 mice from het-
erozygous mating proved to be extremely difficult, which may be related 
to the infertility of the homozygous Nkcc1 KO males (Markadieu and 
Delpire, 2014). As reported previously (Flagella et al., 1999), homozy-
gous mutants gained body weight well after weaning; however, male 
homozygous mutants remained smaller as adults (~70% of male wild- 
type mice), whereas no significant difference in body weight was 
observed in female adults (Fig. 3A). Furthermore, as reported previously 
(Flagella et al., 1999), Nkcc1− /− mice frequently exhibited unusual head 
postures, in which the head was tilted to one side or tilted upward and 
backward with the nose held high. The mutants also exhibited circling 
behavior accompanied by a tendency to engage in rapid spinning and 
shivering. WT littermates behaved normally. 
In view of the possibility that the lower body weight of Nkcc1− /−
mice is associated with a lower brain size that may affect the relative 
kainate concentration in the injected hippocampus, we measured the 
size of the hippocampus. Consistent with the differences in body weight, 
the average area of the hippocampus was ~15% lower in male Nkcc1− /−
mice vs. male WT littermates (which would correspond to a 22% dif-
ference in the size or volume of the hippocampus), whereas no such 
differences were observed in female mice (Fig. 3B). Since the dose-effect 
experiments with kainate in C57BL/6 WT mice did not indicate that a 
20% difference in kainate dose would have any effect on induction of SE 
or incidence of subsequent SRS (see Methods), we decided to use the 
same intrahippocampal kainate dose (0.23 μg = 0.92 nM) in both 
genotypes. 
3.2. Intrahippocampal kainate model 
A total of 59 mice (23 WT kainate, 23 Nkcc1− /− kainate, 13 WT sham 
Fig. 2. Representative EEG recordings following intrahippocampal injection of kainate in homozygous Nkcc1− /− mice (shown in blue) and wildtype (WT) littermates 
(shown in black). All recordings were performed via a depth electrode in the hippocampal kainate focus. A: Control hippocampal EEG before injection of kainate in a 
WT mouse. Note the typical theta oscillations (5–9 Hz), which disappeared during SE in both genotypes. B: Normal hippocampal EEG before injection of kainate in an 
Nkcc1 KO mouse. C: Typical paroxysmal EEG activity during status epilepticus (SE) in a WT mouse. D: Typical paroxysmal EEG activity during SE in an Nkcc1 KO 
mouse. E: Typical electrographic seizure of the high-voltage sharp wave (HVSW) type in a WT mouse. F: HVSW-type electrographic seizure in an Nkcc1 KO mouse. G 
and H: Higher resolution of the HVSWs shown in E and F. I: Typical electrographic seizure of the hippocampal paroxysmal discharge (HPD) type in a WT mouse. J: 
HPD-type electrographic seizure in an Nkcc1 KO mouse. K and L: Higher resolution of the HPDs shown in I and J. M: Spontaneous generalized convulsive (score 5) 
electroclinical seizure in a WT mouse. N: Spontaneous generalized convulsive (score 5) electroclinical seizure in an Nkcc1 KO mouse. Note that the maximal 
amplitude of spikes during electroclinical seizure in M and N was much higher than the maximal amplitude of HVSWs and HPDs, so that the scale bars for amplitude 
(mV) in M and N are different from the scale bars in E-L. Neither the morphology of EEG alterations during SE nor the morphology of spontaneous electrographic or 
electroclinical seizures differed between WT and Nkcc1 KO mice. All EEG alterations and associated videos are also shown for both genotypes in movie S1. 
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controls) was used for these experiments. Sex distribution and losses of 
mice during surgery and SE are shown in Table 2. Final group size for 
comparison of epileptogenesis was 16 WT and 17 KO mice. However, 
some mice lost their electrode head assembly during the 3 months of the 
experiment, so that group size differed between the video-EEG moni-
toring periods at 4-5 and 12-13 weeks illustrated in Fig. 1. 
3.2.1. Status epilepticus 
Before injection of kainate, hippocampal EEG recordings generally 
showed typical theta oscillations (5–9 Hz) without obvious differences 
in WT vs. KO mice (Fig. 2A,B and movie S1). Following injection of 
kainate (0.23 μg) under anesthesia with chloral hydrate, it took about 5- 
7 h on average before SE started (see Fig. 4A). As reported previously by 
us and other groups in studies on different mouse strains (Riban et al., 
2002; Maroso et al., 2011; Twele et al., 2016a, 2016b), the limbic SE 
induced by kainate was characterized by continuous activity of spikes or 
spike-and-waves and polyspikes in the ipsilateral hippocampal EEG 
(Fig. 2C,D and movie S1). Mice were either immobile or exhibited clonic 
movements of the forelimbs; furthermore, in several of the mice inter-
mittent generalized convulsive seizures (Racine stage 3, 4, or 5) were 
observed; these were associated with concomitant high frequency spikes 
or polyspikes in the hippocampal recordings. Average SE duration was 
about 5-6 h (Fig. 4B). 
Five of the 22 WT mice did not develop SE after kainate compared to 
1/23 KO mice (P = 0.0758). As shown in Table 2, mortality during or 
after SE was 1/17 in WT and 5/22 KO, which was not significantly 
different (P = 0.178). Mice without SE were not used for analysis of 
epileptogenesis (see below). 
When comparing latency to SE and SE duration in WT vs. Nkcc1− /−
mice in pooled data on male and female animals, no significant differ-
ences were observed (Fig. 4A, B). In addition to continuous non-
convulsive (limbic) seizure activity during SE, intermittent 
electroclinical seizures (stage 3-5) were observed in both mouse geno-
types during SE. Such seizures were observed in 67% of KO vs. 50% of 
WT mice (P = 0.333). Median number of such seizures was 1.5 (range 0- 
41) in Nkcc1− /− mice vs. 0.5 (range 0-3) in WT mice (P = 0.0276; 
Fig. 4E), indicating that the SE was more severe in the KO mice 
compared to WT littermates. Interestingly, in terms of seizure frequency 
during SE, a bimodal distribution was observed in the KO mice, with five 
mice exhibiting a much higher number of seizures than the rest of the 
group (Fig. 4E). The incidence and frequency of electroclinical seizures 
during SE in individual animals are also illustrated in a heat map 
(Fig. S1). The severity of clinical seizures recorded during SE did not 
significantly differ between genotypes (Fig. 4F). Notably, however, stage 
5 seizures were almost exclusively observed in the KO mice. 
With respect to sex differences, female WT mice exhibited a signifi-
cantly longer latency to SE than male WT mice (P = 0.0081; Fig. 4C), 
whereas no significant sex difference was seen in Nkcc1− /− mice. The 
latency to SE onset was significantly higher in male Nkcc1− /− mice than 
in male WT mice, whereas such a genotype difference was not observed 
in females (Fig. 4C). No significant sex differences within each genotype 
were observed in SE duration (Fig. 4D) or in the severity of clinical 
seizures during SE. In male Nkcc1− /− mice, the number of clinical sei-
zures during SE (9.8 ± 4.5) was significantly higher than the number of 
such seizures in male WT mice (0.57 ± 0.3; P = 0.0469), whereas no 
such difference was observed in female mice (4 ± 2.8 vs. 0.89 ± 0.35; P 
= 0.3339), indicating a sex difference. 
3.2.2. Increase of hippocampal NKCC1 mRNA following SE 
Whether an SE induced by intrahippocampal injection of kainate in 
mice enhances the hippocampal expression of NKCC1 is not known. In 
the pilocarpine model, Li et al. (2008) reported a maximum increase of 
NKCC1 mRNA in the hippocampus at 24 h after SE. 
Twenty-four h after intrahippocampal kainate injection in WT mice, 
a significant about 4-fold increase in NKCC1 mRNA expression was 
determined in the ipsilateral hippocampus (Fig. S2A), while KCC2 
mRNA expression was not altered (Fig. S2B). Thus, the present model 
makes it possible to compare the progression and manifestation of epi-
lepsy in the WT animals, where NKCC1 upregulation takes place 
Fig. 3. Body weight at time of intrahippocampal kainate injection (A) and size 
of the hippocampus (B) in homozygous Nkcc1− /− mice and wildtype (WT) lit-
termates. Mice were 10-15 weeks of age at time of intrahippocampal kainate 
injection. The size of the contralateral hippocampus (at − 1.34 mm from 
bregma) was measured at the end of the experimental period illustrated in 
Fig. 1. Data from both sexes are shown for each genotype. Data are shown as 
boxplots with whiskers from minimum to maximal values; the horizontal line in 
the boxes represents the median value. In addition, individual data are shown. 
Significant group differences are indicated by asterisks (*P < 0.05; **P <
0.0001). Because data were normally distributed, ordinary one-way ANOVA 
with posthoc testing by Holm-Sidak’s multiple comparisons test were used for 
statistical analyses. 
Table 2 
Group size in the intrahippocampal kainate model. Group differences were 
analyzed by Barnard’s test; see text for results (no significant inter-group dif-
ferences were found).  
Group size Wildtype 
littermates 
Nkcc1− /−
Initial 23 (11 males, 12 
females) 
23 (13 males, 10 
females) 
Mortality during anesthesia 1 (female) 0 
Mortality during or after SE 1 (male) 5 (3 males, 2 
females) 
No SE 
(not used for final analysis of epilepsy) 
5 (3 males, 2 
females) 
1 (female) 
Final group size for comparison of 
kainate-induced epileptogenesis 
16 (7 males, 9 
females) 
17 (10 males, 7 
females)  
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promptly after SE, with the KOs that have no NKCC1 at all. 
3.2.3. Latency to onset of spontaneous seizures after SE 
As described by Heinrich et al. (2011) and us (Twele et al., 2016a) 
previously, following spontaneous termination of SE, the hippocampal 
EEG may return to basal activity, interrupted by few low voltage spikes. 
Onset of epilepsy following such latent period is indicated by the 
occurrence of spontaneous electrographic seizures, typically first 
HVSWs and then HPDs, which may progress into electroclinical seizures 
(Heinrich et al., 2011; Twele et al., 2016a). As reported previously for 
C57BL/6 mice (Ndode-Ekane and Pitkänen, 2013; Twele et al., 2016a), 
when electrographic seizures were used to indicate the onset of epilepsy, 
almost no seizure-free latent period was observed in the WT mice. A 
similar observation was made in the KO mice. Average latent period was 
25.1 h (range 0–158 h) in WT vs. 23.1 h (0–57 h) in KO mice, respec-
tively. All data were also separately calculated for male and female mice; 
no significant sex differences were observed (cf., Fig. S1). 
3.2.4. Incidence and frequency of spontaneous electrographic seizures after 
SE 
The incidence of SRS was determined by continuous (24/7) video- 
EEG monitoring at 4-5 and 12-13 weeks after kainate (see Fig. 1). As 
illustrated in Fig. 5A, 77% of WT mice exhibited spontaneous recurrent 
electrographic seizures (HVSWs and/or HPDs) at 4-5 weeks after kai-
nate. Median frequency of such seizures was 11/h (Fig. 5C). At 12-13 
weeks after kainate (Fig. 5B,D), the median frequency of electrographic 
Fig. 4. Characteristics of status epilepticus (SE) in 
homozygous Nkcc1− /− mice and wildtype (WT) lit-
termates. Data are shown as boxplots with whiskers 
from minimum to maximal values; the horizontal line 
in the boxes represents the median value. In addition, 
individual data are shown. Because of disturbances in 
EEG derivation and technical problems with some of 
the video recordings, not all mice could be used for 
final analysis of data, accounting for the lower sam-
ple size compared to Table 2. Significant group dif-
ferences are indicated by asterisks (*P < 0.05). For 
statistical analyses, the Mann-Whitney U test was 
used for the data in A, B, E, D, and F while data in C 
and D were analyzed by nonparametric ANOVA 
(Kruskal-Wallis test) with posthoc Dunn’s multiple 
comparisons test. A: Latency to onset of SE after 
kainate injection. Kainate was injected into the hip-
pocampus under anesthesia with chloral hydrate, 
which explains the long latency to SE onset. B: SE 
duration, as determined by the hippocampal EEG. C 
and D: SE latency and duration calculated separately 
for males and females. E: Number of clinical seizures 
during SE. Typically, the SE after intrahippocampal 
kainate was nonconvulsive (limbic), but intermittent 
electroclinical seizures were observed in 50% (wild-
type) or 67% (KO) of the mice. Note the bimodal 
distribution of clinical seizures in the KO mice in that 
five mice exhibited a higher number of seizures than 
the rest of the group. F: Average severity of the 
electroclinical seizures illustrated in E. In each 
mouse, the severity of electroclinical seizures was 
averaged and used for the group data illustrated in 
this figure.   
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seizures (19.5/h) was not statistically different (P = 0.5519). The indi-
vidual frequency of electrographic seizures in WT and KO mice at 4-5 
and 12-13 weeks after kainate is also shown in a heat map (Fig. S1). 
When HVSWs and HPDs were analyzed separately in WT mice, the 
median frequency of HVSWs was 10.5/h at 4-5 weeks and 15.8/h at 12- 
13 weeks (P = 0.5781), whereas the median frequency of HPDs was 0.5/ 
h at 4-5 weeks and 1/h at 12-13 weeks (P = 0.3828), respectively. 
As shown in Fig. 5A,B, the incidence of electrographic SRS was not 
significantly different in Nkcc1− /− mice. However, the frequency of 
electrographic seizures was significantly lower in Nkcc1-KO vs. WT mice 
at 4-5 weeks after SE (Fig. 5C). 
Both the incidence and frequency of HVSWs were higher than those 
of HPDs in WT mice (Fig. 6A-F). The incidence of HVSWs was not 
different between WT and KO mice at both 4-5 or 12-13 weeks after 
kainate; however, at 12-13 weeks the incidence of HPDs was signifi-
cantly lower in KO than WT mice (Fig. 6D). The frequency of HVSWs was 
significantly lower in KO mice at 4-5 weeks after kainate (Fig. 6E), ac-
counting for the lower frequency of electrographic seizures illustrated in 
Fig. 5C. Furthermore, the frequency of HPDs was significantly lower at 
12-13 weeks after SE (Fig. 6F). Finally, all the data above were sepa-
rately calculated for male and female mice, but no significant sex dif-
ferences were observed (not shown). 
3.2.5. Incidence and frequency of spontaneous electroclinical seizures after 
SE 
As shown in Fig. 7A, 75% of WT mice exhibited spontaneous 
recurrent electroclinical seizures at 4-5 weeks after kainate. Median 
frequency of such seizures was 2.5 per week (Fig. 7C). However, at 12- 
13 weeks after kainate, the incidence of electroclinical seizures signifi-
cantly decreased to 33% (P = 0.0147 vs. 4-5 weeks) (Fig. 7B). 
Furthermore, median frequency of such seizures in WT mice signifi-
cantly decreased from 2.5 seizures per week (range 0-25) at 4-5 weeks to 
0 seizures per week (range 0-81) at 12-13 weeks (P = 0.0171)(Fig. 7D). 
As shown in Fig. 7D, 12/13 WT mice had a seizure frequency around 
zero. One WT mouse in this group exhibited a very high seizure fre-
quency (~80 seizures per week) and turned out to be a statistical outlier 
(see legend to Fig. 7). 
In Nkcc1− /− mice, incidence and frequency of electroclinical seizures 
were not significantly different from WT mice at 4-5 weeks after kainate 
(Fig. 7A, C; but see section 3.2.7). However, at 12-13 weeks after kai-
nate, both incidence and frequency of electroclinical seizures were 
significantly higher compared to WT controls (Fig. 7B, D), indicating a 
pro-epileptogenic effect of NKCC1 deletion. The individual distribution 
of electroclinical seizures over the two one-week periods of continuous 
video/EEG monitoring is illustrated in Fig. S1. All data were also sepa-
rately calculated for male and female mice; no significant sex differences 
were observed (cf., Fig. S1). Three mice (one WT, two KO) died during 
the chronic phase of epilepsy as shown in Fig. S1. 
3.2.6. Comparison of epilepsy in Nkcc1− /− mice with few vs. numerous 
clinical seizures during SE 
As described in 3.2.1 and shown in Fig. 4E and S1, two subgroups of 
Fig. 5. Incidence and frequency of spontaneous electrographic seizures recorded at 4-5 and 12-13 weeks after intrahippocampal kainate injection in homozygous 
Nkcc1− /− mice and wildtype (WT) littermates. In A and B, incidence of electrographic seizures is shown as percentage, whereas seizure frequencies illustrated in C 
and D are shown as boxplots with whiskers from minimum to maximal values; the horizontal line in the boxes represents the median value. In addition, individual 
data are shown. Sample size is 13 WT and 16 KO mice at 4-5 weeks and 10 WT and 13 KO mice at 12-13 weeks, respectively. Because of disturbances in EEG 
derivation or loss of electrode assemblies, not all mice could be used for final analysis of data, explaining the lower sample size compared to Table 2. Furthermore, 
some mice lost their electrode assemblies between the 4 and 12 weeks recording periods, resulting in the lower sample size at 12 weeks. Significant group differences 
are indicated by asterisks (**P < 0.01). For statistical analyses, Barnard’s test was used for the incidence data in A and B, while frequency data in C and D were 
analyzed by the Mann-Whitney U test. A: Incidence of electrographic seizures (HVSWs and HPDs) at 4-5 weeks after status epilepticus (SE). B: Incidence of elec-
trographic seizures (HVSWs and HPDs) at 12-13 weeks after SE. C: Frequency of electrographic seizures (HVSWs and HPDs) at 4-5 weeks after SE. D: Frequency of 
electrographic seizures (HVSWs and HPDs) at 12-13 weeks after SE. All data were also separately calculated for male and female mice; no significant sex differences 
were observed (not shown). 
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Fig. 6. Incidence and frequency of spontaneous electrographic seizures (separately shown for HVSWs and HPDs) recorded at 4-5 and 12-13 weeks after intra-
hippocampal kainate injection in homozygous Nkcc1− /− mice and wildtype (WT) littermates. In A-D, incidence of electrographic seizures is shown as percentage, 
whereas seizure frequencies illustrated in E and F are shown as boxplots with whiskers from minimum to maximal values; the horizontal line in the boxes represents 
the median value. In addition, individual data are shown. See Fig. 5 legend for details on sample size. Significant group differences are indicated by asterisks (*P <
0.05; **P < 0.01). For statistical analyses, Barnard’s test was used for the incidence data in A, B, C, and D, while frequency data in E and F were separately analyzed 
for HVSWs and HPDs by the Mann-Whitney U test. A: Incidence of HVSWs at 4-5 weeks after status epilepticus (SE).). B: Incidence of HVSWs at 12-13 weeks after SE. 
C: Incidence of HPDs at 4-5 weeks after status epilepticus (SE).). D: Incidence of HPDs at 12-13 weeks after SE. E: Frequency of HVSWs and HPDs at 4-5 weeks after 
SE. F: Frequency of HVSWs and HPDs at 12-13 weeks after SE. All data were also separately calculated for male and female mice; no significant sex differences were 
observed (not shown). 
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Nkcc1 KO mice could be distinguished in terms of number of convulsive 
seizures during SE: (i) KO mice with no or few (1-2) seizures, and (ii) KO 
mice with numerous (13-41) seizures. We analyzed these two subgroups 
separately in order to test whether they differed in the consequences of 
SE. As shown in Figs. S1 and S3, no significant differences were found. 
The incidence of electrographic seizures (Fig. S3A) and electroclinical 
seizures (Fig. S3E) tended to be higher in the subgroup with the more 
severe SE, but the difference was not statistically significant. Further-
more, the severity of neuronal damage in CA1 and CA3c was the same in 
both subgroups (see below). Thus, increased SE severity was not the 
cause of the more severe epilepsy phenotype in Nkcc1 KO mice. 
3.2.7. Calculation of effect size of intergroup differences in frequency of 
spontaneous seizures by estimation statistics 
In addition to the traditional presentation of data on seizure fre-
quencies, we used estimation statistics and graphics to visualize effect 
sizes. The primary aim of estimation statistics is to report an effect size 
along with its confidence interval, the latter of which is related to the 
precision of the estimate (Ho et al., 2019). As shown in Fig. 8A,B, esti-
mation statistics indicated a similar effect size for the decrease in fre-
quency of electrographic seizures in Nkcc1 KO mice vs. WT littermates at 
both 4-5 and 12-13 weeks after SE. On the contrary, at both time points 
electroclinical seizures increased with similar effect size in Nkcc1 KO 
mice vs. WT littermates. Thus, the estimation graphics in Fig. 8 indicate 
that at both 4-5 and 12-13 weeks, there was enhanced progression from 
electrographic to electroclinical seizures in Nkcc1 KO mice compared to 
WT littermates. 
3.2.8. Severity and duration of spontaneous electroclinical seizures after SE 
As shown in Fig. S4A, most spontaneous electroclinical seizures were 
secondarily generalized convulsive (stage 5) seizures. Seizure severity 
did not differ significantly between WT and KO mice. The average 
duration of electroclinical seizures was ~45 s at both 4-5 weeks and 12- 
13 weeks after SE without any significant inter-group differences in the 
WT and KO mice (Fig. S4B). All data were also separately calculated for 
male and female mice; no significant sex differences were observed (not 
shown). 
3.2.9. Histological alterations following SE 
As reported previously (Bouilleret et al., 1999; Riban et al., 2002), 
intrahippocampal kainate injection and the resulting SE caused severe 
neuropathological changes in the ipsilateral hippocampus, being char-
acterized by almost complete loss of pyramidal neurons in the CA1 and 
CA3c layers and a marked GCD when examined at ~3 months after 
kainate injection (Fig. 9). No alterations were observed in the contra-
lateral hippocampus. When the severity of the changes in the ipsilateral 
Fig. 7. Incidence and frequency of spontaneous electroclinical seizures recorded at 4-5 and 12-13 weeks after intrahippocampal kainate injection in homozygous 
Nkcc1− /− mice and wildtype (WT) littermates. In A and B, incidence of electrographic seizures is shown as percentage, whereas seizure frequencies illustrated in C 
and D are shown as boxplots with whiskers from minimum to maximal values; the horizontal line in the boxes represents the median value. In addition, individual 
data are shown. Sample size is 16 WT and 17 KO mice at 4-5 weeks and 15 WT and 15 KO mice at 12-13 weeks, respectively. Significant differences between Nkcc1− / 
− mice and WT littermates are indicated by asterisks (*P < 0.05; **P < 0.01), whereas significant differences within each group between the data at 12 vs. 4 weeks 
are indicated by the hash sign (#P < 0.05). For statistical analyses, Barnard’s test was used for the incidence data in A and B, while frequency data in C and D were 
analyzed by the Mann-Whitney U test. Differences within each group between the data at 12 vs. 4 weeks in C and D were analyzed by the Wilcoxon signed rank test. 
A: Incidence of electroclinical seizures at 4-5 weeks after status epilepticus (SE). A: Incidence of electroclinical seizures at 12-13 weeks after SE. C: Frequency of 
electroclinical seizures 4-5 weeks after SE. D: Frequency of electroclinical seizures at 12-13 weeks after SE. Note that Grubb’s test indicated that the WT mouse with 
81 seizures per week in D is an outlier (see also Fig. S3D). All data were also separately calculated for male and female mice; no significant sex differences were 
observed (not shown). 
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hippocampus was scored, no significant differences between WT and 
Nkcc1-KO mice were observed for neurodegeneration in CA1 and CA3c 
(Fig.10A,B) or GCD (Fig. 10C). When neurons in the dentate hilus were 
counted, comparable neuronal numbers and densities were obtained for 
WT and Nkcc1-KO mice after kainate, which did not significantly differ 
from sham controls (Fig.10D,F). However, the area of the ipsilateral 
hilus was significantly increased in WT mice after kainate, which was 
not observed in Nkcc1-KO mice (Fig.10E). All data were also separately 
calculated for male and female mice; no significant sex differences were 
observed (not shown). 
4. Discussion 
Epileptogenesis has been associated with an increased neuronal 
expression of NKCC1 in several studies (e.g., Li et al., 2008; Koyama 
et al., 2012; Marguet et al., 2015; Stamboulian-Platel et al., 2016; 
Kourdougli et al., 2017; Auer et al., 2020; Liu et al., 2020). In the present 
work, we used Nkcc1 WT and KO mice in the intrahippocampal kainate 
model of mesial TLE to address the question whether NKCC1 upregu-
lation in the brain is a necessary condition for the induction and pro-
gression of epilepsy. Our present observation of a robust hippocampal 
upregulation of NKCC1 in the WT animals within 24 h after SE provides 
an excellent basis for a meaningful comparison between the two geno-
types in the present context. 
The main findings of the present study are that (1) homozygous 
Nkcc1− /− mice exhibit a more severe SE with more generalized 
convulsive seizures than WT littermates, and (2) epileptogenesis after SE 
significantly differs between genotypes. Estimation graphics indicated 
that Nkcc1 mice exhibit less spontaneous electrographic seizures but 
more electroclinical seizures than WT mice at both 4-5 and 12-13 weeks 
after kainate. Thus, surprisingly (see Introduction), the epileptic 
phenotype of the Nkcc1 mice is more severe compared to WT mice. More 
generally, our data suggest that NKCC1 is dispensable for the induction, 
progression and manifestation of epilepsy. 
The progressive evolution of electrographic and electroclinical sei-
zures after intrahippocampal kainate injection in mice has been 
described previously by several groups, including our own (Riban et al., 
2002; Heinrich et al., 2011; Maroso et al., 2011; Twele et al., 2016a; 
Sandau et al., 2019). During the latent period, the first electrographic 
signs of seizure activity recorded in the ipsilateral hippocampus are 
typically HVSWs, followed by HPDs and finally secondarily generalized 
electroclinical seizures, which subsequently spread to the cerebral 
Fig. 8. Different frequencies of spontaneous recurrent seizures in WT vs. Nkcc1 KO mice as analyzed with estimation statistics. In each graph, the median differences 
between WT and KO are shown in the Gardner-Altman estimation plots. Both groups are plotted on the left axes; the mean difference is plotted on a floating axis on 
the right as a bootstrap sampling distribution. The mean difference is depicted as a dot; the 95% confidence intervals are indicated by the ends of the vertical error 
bars. A: Frequency of electrographic seizures at 4-5 weeks after kainate. The unpaired median difference between 0 and KO is − 9.5 [95.0%CI -28.0, 2.0]. The P value 
of the two-sided permutation t-test is 0.0392. B: Frequency of electrographic seizures at 12-13 weeks after kainate. The unpaired median difference between WT and 
KO is − 12.0 [95.0%CI -31.8, 8.5]. The P value of the two-sided permutation t-test is 0.0872. C: Frequency of electroclinical seizures at 4-5 weeks after kainate. The 
unpaired median difference between WT and KO is 3.0 [95.0%CI -1.5, 5.0]. The P value of the two-sided permutation t-test is 0.0082. D: Frequency of electroclinical 
seizures at 12-13 weeks after kainate. For the data in D, one outlier (see Fig. 7D) was removed by the method of Grubb. The unpaired median difference between WT 
and KO is 3.0 [95.0%CI 0.0, 3.0]. The P value of the two-sided permutation t-test is 0.0098. If the potential outlier is not deleted, the unpaired median difference 
between WT and KO is 3.0 [95.0%CI 0.0, 3.0]. The P value of the two-sided permutation t-test is 0.0098. Thus, the potential WT outlier does not affect the analysis of 
the group difference. 
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cortex. The present findings thus indicate that NKCC1 deletion leads to 
increased progression of focal electrographic (nonconvulsive) seizures 
to secondarily generalized convulsive electroclinical seizures in the 
chronic phase of epilepsy in this model. 
The finding that the incidence and frequency of electroclinical sei-
zures in WT mice was significantly lower at 12-13 vs. 4-5 weeks after 
kainate was unexpected and may be due to the genetic background of 
these mice (see Methods), because we did not observe such a difference 
in another (NMRI) mouse strain (Schidlitzki et al., 2017; Schidlitzki 
et al., 2020). Remission of electroclinical seizures as determined in the 
WT mice here was not observed in Nkcc1− /− mice. However, as reported 
previously by several groups for C57BL/6 and some other mouse strains 
(Riban et al., 2002; Maroso et al., 2011; Duveau et al., 2016; Schidlitzki 
et al., 2017; Sandau et al., 2019; Schidlitzki et al., 2020), the WT mice of 
the present study exhibited frequent spontaneous electrographic sei-
zures (HVSWs and HPDs) at both early and late time points after kainate, 
indicating chronic epilepsy. In this respect, it is important to note that 
most groups using the intrahippocampal kainate model of TLE only 
monitor the frequent electrographic seizures but not the infrequent 
electroclinical seizures. 
Until recently, it was not known whether an SE induced by intra-
hippocampal kainate injection increases NKCC1 expression in the hip-
pocampus similar to the changes reported for the pilocarpine model (Li 
et al., 2008; Brandt et al., 2010; Kourdougli et al., 2017). In the present 
study, we found that hippocampal NKCC1 mRNA expression of WT mice 
is significantly (~400%) increased already 24 h after the kainate- 
induced SE, which is similar to the findings of Li et al. (2008) in the 
lithium-pilocarpine model in mice. Cell-specific information cannot be 
obtained by studying NKCC1 mRNA expression in brain tissue samples 
(Virtanen et al., 2020). With respect to cell-specific labeling of NKCC1 
by immunohistochemistry as done in several previous studies in epilepsy 
models, a serious shortcoming in such studies is the absence of KO- 
validated immunohistochemical procedures (for review, see Virtanen 
et al., 2020). This problem is accentuated by the fact that NKCC1 shows 
a wide distribution in a variety of cells within the brain, including 
different types of glial cells, brain capillary endothelial cells, and neu-
rons. Moreover, neurons are likely to make a minor contribution to total 
tissue levels of NKCC1 mRNA and protein (Virtanen et al., 2020). In the 
Nkcc1− /− mice used here, NKCC1-related alterations can obviously not 
occur, thus providing a tool to determining the role of NKCC1 in epi-
leptogenesis following intrahippocampal kainate injection, although the 
limitations of constitutive KO should be kept in mind. 
The Nkcc1− /− mice used in these previous and present experiments 
are conventional (constitutive) KO mice, in which the target gene is 
permanently inactivated in the germ line and, consequently, in all cells 
of the animal at all stages of development. One of the main disadvan-
tages of constitutive gene KO is that the deletion could activate 
compensatory genes that interfere with the readouts examined in the 
affected mice (Caceres et al., 2018). The global Nkcc1 KO has a high 
degree of mortality at baseline, and therefore the mice that survive may 
have specific compensatory mechanisms (however, not necessarily 
within the brain) to overcome the lack of NKCC1. In theory, this might 
render the surviving animals more susceptible to higher progression of 
electrographic to electroclinical seizures. Thus, further work is needed 
on conditional and inducible KO mouse models which allow the acti-
vation/inactivation of a target gene at a given time point and within a 
particular tissue or cell type (Caceres et al., 2018). Tissue-specific, 
conditional Nkcc1− /− mice have been developed (Antoine et al., 
2013), but, to our knowledge, not yet used for studying the role of cell- 
specific expression of NKCC1 in seizures and epilepsy. When judging the 
utility of the full KO mouse as used here, it is important to note that the 
cellular targets of bumetanide’s effects on seizures and epilepsy have not 
been identified sufficiently. Therefore, using cell-specific conditional 
NKCC1 KO mice at present might not be more advantageous – perhaps 
the opposite. Thus, we believe that the present findings are highly 
interesting for a large number of researchers who work on NKCC1 as a 
potential drug target. Moreover, the present data on the constitutive KO 
are likely to catalyze work on more specific genetic manipulations, 
especially as our results raise the somewhat surprising possibility that 
blocking NKCC1 in the CNS may not be beneficial in the prevention of 
seizures. 
In the present study, the typical neurodegeneration and granule cell 
dispersion occurring in the ipsilateral hippocampus of the intra-
hippocampal kainate mouse model (Riban et al., 2002) was not altered 
by NKCC1 deletion. However, the increased size of the dentate hilus was 
not observed in NKCC1 KO mice. An increase in hilus area (or volume) is 
often seen in rodent models of TLE and has been related to edema, but 
also astrogliosis or ectopic granule cell development (Lassmann et al., 
1984; Brandt et al., 2004; McCloskey et al., 2006; Scharfman and Pierce, 
Fig. 9. Photomicrographs of the ipsilateral hippocampus of homozygous 
Nkcc1− /− mice and wildtype (WT) littermates. Animals were perfused at ~3 
months after intrahippocampal kainate injection (or sham injection) and brains 
were stained with thionin for histological analysis. Shown are representative 
photomicrographs of ipsilateral hippocampi of (A) a sham-operated WT mouse, 
(B) a kainate-treated WT mouse, and (C) a kainate-treated Nkcc1− /− -mouse. 
Scale bar = 200 μm. In B and C, the CA1 and CA3c pyramidal cell layers are 
almost completely damaged. Note the marked granule cell dispersion in both B 
and C. As reported previously (Bouilleret et al., 1999; Riban et al., 2002; 
Gröticke et al., 2008; Schidlitzki et al., 2017), no obvious structural changes 
were seen in the contralateral hippocampi of kainate-injected mice (not shown). 
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2012). NKCC1 is highly expressed on the luminal membrane of the ce-
rebral vascular endothelium and seems to be critically involved in ionic 
edema and swelling of the brain parenchyma following brain insults, 
including SE (Kahle et al., 2009; Simard et al., 2010; Wallace et al., 
2011; Mokgokong et al., 2014). In addition, glial expression of NKCC1 is 
involved in cell swelling (Hochman, 2012). Thus, the function of NKCC1 
in brain endothelial and glial cells may explain the lack of increase in 
hilar volume in response to kainate observed in Nkcc1− /− mice. 
The present finding that NKCC1 deletion does not exert anti-
epileptogenic effects in the intrahippocampal kainate model is in line 
with previous pharmacological experiments of Nardou et al. (2009), 
using an in vitro preparation composed of two intact interconnected rat 
hippocampi in a three compartment chamber, in which seizures are 
induced by kainate in one hippocampus, thus allowing to investigate the 
effects of drugs on both the seizure propagation to the other hippo-
campus and seizure-induced epileptogenic mirror focus formation. They 
reported that inhibition of NKCC1 by bumetanide (10 μM) did not pre-
vent generation of kainate-induced seizures and their propagation to the 
“drug-naive” contralateral hippocampus. Bumetanide also failed to 
prevent the formation of an acute epileptogenic mirror focus in the 
contralateral hippocampus that had not been exposed to kainate, but 
only to propagating seizures originating from the drug-exposed hippo-
campus. These findings demonstrate that blocking NKCC1 activity alone 
does not prevent epileptogenesis, which is further substantiated by our 
previous in vivo experiments with bumetanide in the rat pilocarpine 
model (Brandt et al., 2010) and the present experiments with genetic 
NKCC1 deletion in the intrahippocampal kainate mouse model of TLE. 
From a pharmacological point of view, it is important to add in the 
present context that applying bumetanide at the level of the whole an-
imal or directly into the brain does not, either, provide any information 
on the likely heterogenous effects mediated by the drug in various kinds 
of cells and tissues with significant levels of NKCC1 expression (see 
Russell, 2000; Virtanen et al., 2020). Thus, we feel that our present data 
on the full Nkcc1 KO are of much relevance for current and future studies 
in the present field of research. 
In conclusion, despite extensive research, it remains unknown 
whether changes in NKCC1 and KCC2 expression and function act as 
protective or adaptive mechanisms during brain injury such as induced 
by SE or TBI. This important issue should, obviously, deserve much more 
attention in the interpretation of the effects of NKCC1-targeting drugs in 
epilepsy and in their possible therapeutic implementation. The present 
findings in Nkcc1− /− mice do not support the widely held notions that 
NKCC1 and its upregulation in the brain are closely involved in epi-
leptogenesis and manifestation of epilepsy, and that using inhibitors of 
NKCC1 is a useful strategy for preventing or modifying epilepsy. 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.nbd.2021.105297. 
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permeant NKCC1 inhibitors for the treatment of seizures: Pharmacokinetic- 
pharmacodynamic modelling of NKCC1 inhibition by azosemide, torasemide and 
bumetanide in mouse brain. Epilepsy Behav. (in press).  
Heinrich, C., Lahteinen, S., Suzuki, F., Anne-Marie, L., Huber, S., Haussler, U., Haas, C., 
Larmet, Y., Castren, E., Depaulis, A., 2011. Increase in BDNF-mediated TrkB 
signaling promotes epileptogenesis in a mouse model of mesial temporal lobe 
epilepsy. Neurobiol. Dis. 42, 35–47. 
Ho, J., Tumkaya, T., Aryal, S., Choi, H., Claridge-Chang, A., 2019. Moving beyond P 
values: data analysis with estimation graphics. Nat. Methods 16, 565–566. 
Hochman, D.W., 2012. The extracellular space and epileptic activity in the adult brain: 
explaining the antiepileptic effects of furosemide and bumetanide. Epilepsia 53 
(Suppl. 1), 18–25. 
Huberfeld, G., Wittner, L., Clemenceau, S., Baulac, M., Kaila, K., Miles, R., Rivera, C., 
2007. Perturbed chloride homeostasis and GABAergic signaling in human temporal 
lobe epilepsy. J. Neurosci. 27, 9866–9873. 
Johne, M., Römermann, K., Hampel, P., Gailus, B., Theilmann, W., Ala-Kurikka, T., 
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